PBSC Transplant

PROCEDURE2 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Polyphor Ltd.

Conditions

Acute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in RemissionChronic Lymphocytic Leukemia (CLL)Chronic Myelogenous Leukemia (CML)Multiple Myeloma (MM)Myelodysplastic Syndrome (MDS)Myeloproliferative DisordersNon-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission

Phase 1

Haploidentical PBMC Transplant for Severe Congenital Anemias

Active, not recruitingNCT00977691

National Heart, Lung, and Blood Institute (NHLBI)Sickle Cell Anemia

Start: 2009-12-14End: 2026-09-10Updated: 2026-04-23

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

CompletedNCT01413568

Polyphor Ltd.Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Lymphocytic Leukemia (CLL) +5

Start: 2012-04-30End: 2015-12-31Updated: 2016-02-26

Related Papers

Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

2026-05-14

Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.

2026-03-23

Impact of pre-transplant bone marrow cellularity and fibrosis on post-transplant outcomes in sickle cell disease

Blood2025-11-03

The impact of hematopoietic cell transplantation on sickle cell hepatopathy and vice versa

Blood2025-11-03

Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT

Blood Advances2017-04-19103 citations